Breakthrough In Acute Pain Management: FDA Approves First-In-Class Non-Opioid
On Thursday, the U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) 50 mg oral tablets, a first-in-class non-opioid analgesic for the treatment of moderate to severe acute pain in adults.Developed by…












